

CITATION REPORT

List of articles citing

Tocilizumab as a steroid sparing agent for the treatment of Gravesrorbitopathy

DOI: 10.1016/j.ajoc.2017.07.001

American Journal of Ophthalmology Case Reports, 2017, 7, 146-148.

Source: <https://exaly.com/paper-pdf/67155292/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
25	Management of graves myopathy: Thyroid-associated orbitopathy: when should we operate?. <i>Journal of AAPOS</i> , 2018 , 22, 251-252	1.3	3
24	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	85
23	Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications. <i>Frontiers in Endocrinology</i> , 2018 , 9, 810	5.7	0
22	Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 1305-1318	2.9	9
21	Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 281-284	2.8	7
20	New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 104-116	15.2	63
19	Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review. <i>Ophthalmology and Therapy</i> , 2020 , 9, 21-33	5	15
18	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
17	Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy. <i>European Thyroid Journal</i> , 2020 , 9, 17-30	4.2	7
16	Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives. <i>Current Eye Research</i> , 2020 , 45, 1325-1341	2.9	6
15	[Monoclonal antibodies in the treatment of thyroid eye disease]. 2021 , 137, 116-122		
14	Graves Ophthalmopathy. 2021 , 261-271		
13	Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
12	The role of oxidative stress in the pathogenesis of Graves Orbitopathy. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021 , 75, 448-455	0.3	
11	Tocilizumab for the Management of Thyroid-Associated Orbitopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021 ,	1.4	0
10	The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021 , 129, 762-769	2.3	1
9	Biologics for Thyroid Eye Disease. 2022 , 481-498		

8 Steroids and Thyroid Eye Disease. **2022**, 463-469

7 Tocilizumab use in pediatric thyroid eye disease: First documented case.. *American Journal of Ophthalmology Case Reports*, **2022**, 25, 101387 1.3 0

6 Pathophysiology of autoimmune orbital diseases and target therapy for orbital inflammatory and neoplastic diseases. **2022**, 105-120

5 Current concepts regarding Graves Orbitopathy. *Journal of Internal Medicine*, 10.8 1

4 Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. *Indian Journal of Ophthalmology*, **2022**, 70, 2335 1.6 0

3 Teprotumumab. *Advances in Ophthalmology and Optometry*, **2022**, 0.5

2 Cytokines in Thyroid-Associated Ophthalmopathy. **2022**, 2022, 1-12 0

1 Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. Publish Ahead of Print, 0